Changes in immunological parameters in lung cancer patients undergoing immunotherapy with streptococcal preparation OK-432.
We have studied the immunological status of patients treated with streptococcal preparation OK-432. Two KE of OK-432 was injected intramuscularly once every week for more than three years unless the patients died. The natural killer (NK) activity in those patients who underwent curative surgery for lung cancer and had no sign of recurrence was significantly increased (P less than 0.01) during the OK-432 treatment. However, the NK activity in the patients who had persistent disease (non-resected cases, incompletely resected cases or recurrent cases) was not significantly increased in comparison with that before the immunotherapy. Also, in the cases with no clinical symptoms of recurrence, both the lymphoblastogenetic reactions to the mitogens and the IL-2 production were significantly enhanced (P less than 0.01) during the administration of OK-432. Reactions in the SU-PS (polysaccharide taken from the cell-wall fraction of the Streptococcus pyogenes SU strain and containing 7.2% of protein) skin-test appeared to significantly correlate with the immunological status of the patients under OK-432 therapy, but the PHA and PPD skin reactions showed no definitive enhancement. The survival rate of the patients whose SU-PS skin tests were positive during the OK-432 immunotherapy was significantly higher (P less than 0.01) than that of the patients with negative reactions.
Department of Surgery, Kanazawa University School of Medicine, Japan.
Y
Y
Watanabe
J
J
Shimizu
Y
Y
Hashizume
Y
Y
Tsunamura
T
T
Yamada
T
T
Iwa
S
S
Sakai
T
T
Murayama
S
S
Koshimura
M
M
Saito
D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects*; D007167:Immunotherapy; D007376:Interleukin-2 / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000187:drug effects / Q000502:physiology; D008175:Lung Neoplasms / Q000097:blood / Q000276:immunology* / Q000628:therapy; D008213:Lymphocyte Activation / Q000187:drug effects; D010844:Picibanil / Q000627:therapeutic use*; D012882:Skin Tests / Q000379:methods
D007376:Interleukin-2; D010844:Picibanil